Methods and compositions for diagnosis and prognosis of renal injury and renal failure
View Patent ↗The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.
1. A method for evaluating renal status in a subject, comprising:
performing an immunoassay configured to detect Tissue inhibitor of metalloproteinase 2 by introducing a urine sample obtained from the subject into an assay instrument which contacts the urine sample with an antibody which specifically binds for detection Tissue inhibitor of metalloproteinase 2 and generates an assay result indicative of binding of Tissue inhibitor of metalloproteinase 2 to the antibody; and
correlating the assay result generated by the assay instrument to a likelihood that the subject is at risk of a future acute renal injury by using assay result to assign the patient to a predetermined subpopulation of individuals having a known predisposition of a future renal injury; and
treating the patient based on the predetermined subpopulation of individuals to which the patient is assigned, wherein the treatment comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.
2. A method according to claim 1 , wherein said risk of a future acute renal injury is a risk of future acute renal failure (ARF).
3. A method according to claim 2 , wherein said assay result is a measured concentration of Tissue inhibitor of metalloproteinase 2 and said correlation step comprises comparing said measured concentration to a threshold concentration, and assigning an increased likelihood of suffering future ARF to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold or assigning a decreased likelihood of suffering future ARF to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.
4. A method according to claim 1 , wherein said assay result is
a measured concentration of Tissue inhibitor of metalloproteinase 2 and said correlation step comprises comparing said measured concentration to a threshold concentration, and assigning an increased likelihood of suffering future ARF to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold or assigning a decreased likelihood of suffering future ARF to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.
5. A method according to claim 1 , wherein risk of a future acute renal injury is within 30 days of the time at which the body fluid sample is obtained from the subject.
6. A method according to claim 5 , wherein risk of a future acute renal injury is within 48 hours or less of the time at which the body fluid sample is obtained from the subject.
7. A method according to claim 1 , wherein the subject is selected for evaluation of renal status based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF.
8. A method according to claim 1 , wherein the subject is selected for evaluation of renal status based on an existing diagnosis of sepsis.
9. A method according to claim 5 , wherein the risk of a future acute renal injury is within 24 hours of the time at which the body fluid sample is obtained from the subject.